# IGC Pharma Inc. (IGC)

Source: https://www.quantisnow.com/company/IGC
Generated: 2026-11-10T21:24:48.235Z

- Ticker: IGC
- Exchange: AMEX
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001326205
- Website: igcinc.us

## About

India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. The company operates through two segments, Infrastructure Business, and Life Sciences. It buys and sells infrastructure commodities, such as steel, wooden doors, marble, and tiles; rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. The company also develops cannabinoid-based products and therapies, such as Hyalolex for the treatment of patients from anxiety, agitation, dementia, depression, and sleep disorder diseases; hemp-based CBD infused products under the Holief brand name; premium hemp-based CBD infused organic topical and spa line of products under the Herbo brand name; and premium hemp-based CBD infused seltzer under the Sunday Seltzer brand. In addition, it offers offer trading, distillation, tolling, and white labeling services under the Holi Hemp brand; and hemp crude extracts, hemp isolates, and hemp distillates. The company operates in the United States, India, Colombia, and Hong Kong. India Globalization Capital, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

## Latest IGC news and filings

- 2026-11-09 13:00 UTC [Market Insight] [IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/igc-pharma-reports-third-quarter-2026-financial-results-and-provides-6780316)
- 2026-11-06 21:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by IGC Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-igc-pharma-inc-6778776)
- 2026-11-05 15:18 UTC [Market Insight] [IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears](https://www.quantisnow.com/insight/igc-pharmas-alzheimers-agitation-drug-candidate-now-patented-in-the-6775288)
- 2026-10-22 20:02 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by IGC Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-igc-pharma-inc-6755059)
- 2026-10-22 00:32 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by IGC Pharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-igc-pharma-inc-6754078)
- 2026-10-13 12:00 UTC [Market Insight] [IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment](https://www.quantisnow.com/insight/igc-pharma-unveils-prism-ai-platform-to-move-alzheimers-risk-6744180)
- 2026-09-29 20:01 UTC [SEC Form 4] [CEO Mukunda Ram gifted 200,000 shares, decreasing direct ownership by 3% to 6,675,563 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-mukunda-ram-gifted-200000-shares-decreasing-direct-ownership-by-6729148)
- 2026-09-29 20:00 UTC [SEC Form 4] [PFO Grimaldi Claudia gifted 150,000 shares, decreasing direct ownership by 4% to 3,271,092 units (SEC Form 4)](https://www.quantisnow.com/insight/pfo-grimaldi-claudia-gifted-150000-shares-decreasing-direct-ownership-by-6729138)
- 2026-09-28 12:00 UTC [Market Insight] [IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026](https://www.quantisnow.com/insight/igc-pharma-completes-enrollment-in-phase-2-calma-alzheimers-trial-6727136)
- 2026-08-17 12:30 UTC [Market Insight] [IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure](https://www.quantisnow.com/insight/igc-pharma-reports-q2-2026-results-as-calma-alzheimers-trial-6684435)
- 2026-08-11 12:30 UTC [Market Insight] [IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout](https://www.quantisnow.com/insight/igc-pharma-strengthens-regulatory-readiness-as-phase-2-calma-alzheimers-6675094)
- 2026-07-29 12:30 UTC [Market Insight] [IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign](https://www.quantisnow.com/insight/igc-pharma-evaluates-potential-recovery-options-as-federal-jury-verdict-6652901)
- 2026-07-13 22:11 UTC [SEC Form 8-K] [IGC Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/igc-pharma-inc-filed-sec-form-8-k-regulation-fd-disclosure-6635877)
- 2026-07-09 13:00 UTC [Market Insight] [IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow](https://www.quantisnow.com/insight/igc-pharma-to-showcase-ai-portfolio-at-aaic-2026-including-6632577)
- 2026-07-07 13:00 UTC [Market Insight] [IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company](https://www.quantisnow.com/insight/igc-pharma-ceo-and-principal-financial-officer-purchase-more-than-6629683)
- 2026-07-06 20:02 UTC [SEC Form 8-K] [IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/igc-pharma-inc-filed-sec-form-8-k-entry-into-a-6627971)
- 2026-07-01 13:01 UTC [SEC Form 4] [CEO Mukunda Ram was granted 2,226,475 shares, increasing direct ownership by 48% to 6,875,563 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-mukunda-ram-was-granted-2226475-shares-increasing-direct-ownership-6622177)
- 2026-07-01 13:00 UTC [SEC Form 4] [PFO Grimaldi Claudia was granted 2,048,378 shares, increasing direct ownership by 149% to 3,421,092 units (SEC Form 4)](https://www.quantisnow.com/insight/pfo-grimaldi-claudia-was-granted-2048378-shares-increasing-direct-ownership-6622162)
- 2026-06-23 12:30 UTC [Market Insight] [IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow](https://www.quantisnow.com/insight/igc-pharmas-aha-agentic-ai-platform-reduces-alzheimers-data-harmonization-6611985)
- 2026-06-11 12:30 UTC [Market Insight] [IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis](https://www.quantisnow.com/insight/igc-pharma-reaches-previously-disclosed-146-patient-enrollment-target-in-phase-6598340)
- 2026-06-09 12:30 UTC [Market Insight] [Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts](https://www.quantisnow.com/insight/ascendiant-capital-markets-raises-igc-pharma-price-target-to-550-6594685)
- 2026-06-08 20:03 UTC [SEC Form 8-K] [IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/igc-pharma-inc-filed-sec-form-8-k-entry-into-a-6593241)
- 2026-06-02 12:30 UTC [Market Insight] [IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis](https://www.quantisnow.com/insight/igc-pharma-adds-mount-sinai-clinical-site-as-calma-trial-6583396)
- 2026-05-19 21:30 UTC [Market Insight] [IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment](https://www.quantisnow.com/insight/igc-pharma-reports-first-quarter-2026-financial-results-with-calma-6563558)
- 2026-05-15 20:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by IGC Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-igc-pharma-inc-6557044)
- 2026-05-15 12:00 UTC [Market Insight] [IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference](https://www.quantisnow.com/insight/igc-pharma-to-present-tau-pet-biomarker-research-at-2026-global-6555740)
- 2026-04-28 16:15 UTC [Market Insight] [IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase](https://www.quantisnow.com/insight/igc-pharma-advances-caregiver-engagement-as-phase-2-calma-trial-6518158)
- 2026-04-22 12:30 UTC [Market Insight] [IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion](https://www.quantisnow.com/insight/igc-pharma-adds-kerwin-medical-center-in-dallas-to-phase-6509648)
- 2026-04-20 20:01 UTC [SEC Form 8-K] [IGC Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/igc-pharma-inc-filed-sec-form-8-k-entry-into-a-6506564)
- 2026-04-20 12:30 UTC [Market Insight] [IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia](https://www.quantisnow.com/insight/igc-pharma-secures-psilocybin-research-authorization-expanding-focus-on-neuropsychiatric-6506164)
- 2026-04-14 12:30 UTC [Market Insight] [IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout](https://www.quantisnow.com/insight/igc-pharma-reaches-80-enrollment-in-phase-2-calma-trial-6498909)
- 2026-04-08 16:45 UTC [Market Insight] [Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts](https://www.quantisnow.com/insight/ascendiant-capital-markets-raises-igc-pharma-price-target-to-525-6492651)
- 2026-04-07 12:00 UTC [Market Insight] [IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease](https://www.quantisnow.com/insight/igc-pharma-adds-tandem-clinical-research-to-the-calma-trial-6490343)
- 2026-04-06 20:02 UTC [SEC Form 4] [SEC Form 4 filed by Prins Richard K](https://www.quantisnow.com/insight/sec-form-4-filed-by-prins-richard-k-6489200)
- 2026-04-06 20:02 UTC [SEC Form 4] [SEC Form 4 filed by Mukunda Ram](https://www.quantisnow.com/insight/sec-form-4-filed-by-mukunda-ram-6489197)
- 2026-04-06 20:02 UTC [SEC Form 4] [SEC Form 4 filed by Moran James P](https://www.quantisnow.com/insight/sec-form-4-filed-by-moran-james-p-6489192)
- 2026-04-06 20:01 UTC [SEC Form 4] [SEC Form 4 filed by Grimaldi Claudia](https://www.quantisnow.com/insight/sec-form-4-filed-by-grimaldi-claudia-6489189)
- 2026-03-30 21:43 UTC [SEC Form 8-K] [IGC Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/igc-pharma-inc-filed-sec-form-8-k-other-events-financial-6477048)
- 2026-03-30 12:00 UTC [Market Insight] [IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness](https://www.quantisnow.com/insight/igc-pharma-launches-strategic-national-media-partnership-with-new-to-6475872)
- 2026-03-19 13:00 UTC [Market Insight] [IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025](https://www.quantisnow.com/insight/igc-pharma-reports-financial-results-and-clinical-progress-for-the-6460942)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IGC
- Earnings history: https://www.quantisnow.com/earnings/IGC
- Dividend history: https://www.quantisnow.com/dividends/IGC
- Insider transactions: https://www.quantisnow.com/insiders/IGC
- Options chain: https://www.quantisnow.com/options/IGC
- SEC 8-K filings only: https://www.quantisnow.com/company/IGC/8-k
- RSS and alerts for IGC: https://www.quantisnow.com/docs/rss-feeds.md